Valuation: Summit Therapeutics Inc.

Market Cap 10.9B 14.69B 12.73B 12.02B 20.45B 1,408B 20.6B 144B 55.3B 714B 55.19B 53.97B 2,271B P/E 2026 *
-15.8x
P/E 2027 * -15.8x
Enterprise Value 10.43B 14.06B 12.19B 11.5B 19.57B 1,348B 19.71B 137B 52.93B 684B 52.83B 51.66B 2,174B EV / Sales 2026 *
3,570x
EV / Sales 2027 * 257x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
1 day+4.96%
1 week+4.63%
Current month+35.24%
1 month+37.98%
3 months+31.48%
6 months+14.27%
Current year+5.32%
1 week 16.8
Extreme 16.8
18.83
1 month 12.07
Extreme 12.07
18.83
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 24/07/2022
Chief Executive Officer 81 31/03/2020
Director of Finance/CFO 48 01/04/2024
Director TitleAgeSince
Chairman 81 31/01/2020
Director/Board Member 48 30/11/2019
Director/Board Member 55 10/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Executive Officer

100,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+4.96%+4.63%-2.75%+864.40% 14.69B
+5.04%+3.66%+50.62%+103.77% 70.24B
+1.64%-0.18%+34.67%+76.81% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
-0.33%-0.81%+25.90%+11.39% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
+1.15%-1.17%+17.56%-21.92% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-3.95%-5.12%-9.04%+486.08% 14.66B
+0.16%-4.74%+43.58%+152.40% 13.93B
Average +0.07%-2.12%+31.05%+233.26% 28.91B
Weighted average by Cap. +1.19%-0.99%+32.34%+167.45%

Financials

2026 *2027 *
Net sales 2.92M 3.94M 3.41M 3.22M 5.48M 378M 5.52M 38.48M 14.83M 192M 14.8M 14.47M 609M 41.7M 56.22M 48.71M 45.97M 78.23M 5.39B 78.8M 549M 212M 2.73B 211M 206M 8.69B
Net income -691M -932M -808M -762M -1.3B -89.32B -1.31B -9.1B -3.51B -45.31B -3.5B -3.42B -144B -734M -989M -857M -809M -1.38B -94.78B -1.39B -9.66B -3.72B -48.08B -3.71B -3.63B -153B
Net Debt -467M -630M -546M -515M -877M -60.37B -883M -6.15B -2.37B -30.63B -2.37B -2.31B -97.37B -199M -268M -232M -219M -373M -25.66B -375M -2.61B -1.01B -13.02B -1.01B -983M -41.38B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
14/09/26 US$18.42 +4.96% 7,066,883
11/09/26 US$17.55 +3.24% 4,278,137
10/09/26 US$17.00 -3.08% 4,221,476
09/09/26 US$17.54 +1.50% 4,803,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.66GBP
Average target price
21.55GBP
Spread / Average Target
+57.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!